Core Viewpoint - Tiger Med has seen a significant increase in stock price, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Changsheng Fund hold a total of 343,900 shares of Tiger Med, with a floating profit of approximately 873,500 CNY based on the previous day's closing price of 50.78 CNY and the current price of 53.32 CNY [2][8]. - The Changsheng Medical Quantitative Stock A fund holds 180,900 shares, representing 7.23% of the fund's net value, while the Changsheng Pension Health Mixed A fund holds 163,000 shares, representing 7.98% of the fund's net value [3][7].

Core Viewpoint - Tiger Med has seen a significant stock price increase, with a 5% rise on March 27, reaching 53.32 CNY per share, and a cumulative increase of 6.82% over three consecutive days [1][5]. Company Overview - Tiger Med, officially known as Hangzhou Tiger Medical Technology Co., Ltd., was established on December 15, 2004, and went public on August 17, 2012. The company is located in Hangzhou, Zhejiang Province [1][5]. - The main business involves providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6]. Revenue Composition - The revenue composition of Tiger Med is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other supplementary services for 2.19% [6]. Fund Holdings - Three funds under Founder Fubon hold a total of 443,100 shares of Tiger Med, with a floating profit of approximately 1.1255 million CNY based on the stock price increase [2][7]. - The specific funds and their holdings are as follows: - Founder Fubon Jin Lifang One-Year Holding Mixed Fund (019226) holds 381,500 shares, representing 3.88% of the fund's net value [3][8]. - Founder Fubon Emerging Growth Mixed Fund (008602) holds 47,500 shares, representing 3.72% of the fund's net value [4][9]. - Founder Fubon Xincheng 12-Month Holding Mixed Fund (015514) holds 14,100 shares, representing 3.66% of the fund's net value [4][9].

3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.96亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 其中，工银前沿医疗股票A（001717）四季度持有股数650万股，占基金净值比例为4.19%，位居第九大 重仓股。根据测算，今日浮盈赚取约1651万元。连续3天上涨期间浮盈赚取2106万元。 工银医疗保健股票（000831）四季度持有股数147.07万股，占基金净值比例为3.48%，位居第六大重仓 股。根据测算，今日浮盈赚取约373.56万元。连续3天上涨期间浮盈赚取476.51万元。 工银健康产业混合A（020558）四季度持有股数12.63万股，占基金净值比例为2.34%，位居第九大重仓 股。根据测算，今日浮盈赚取约32.08万元。连续3天上涨期间浮盈赚取40.92万元。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 MACD金叉信号形成，这些股涨势不错 ...

Core Viewpoint - Tiger Med has experienced a significant stock price increase, with a 5% rise on March 27, reaching 53.32 CNY per share, and a cumulative increase of 6.82% over three consecutive days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][6]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][6]. Fund Holdings - Three funds under Huatai-PineBridge have significant holdings in Tiger Med, totaling 3.0177 million shares. Based on the previous day's closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a floating profit of approximately 7.6649 million CNY for the day and 9.7772 million CNY over the three-day increase [2][7]. - The specific fund holdings include: - Huatai-PineBridge CSI Biotech Index (LOF) A: 1.2511 million shares, representing 3.22% of the fund's net value, with a recent increase of 31,900 shares [3][8]. - Huatai-PineBridge Precision Medicine Index (LOF) A: 1.0487 million shares, representing 5.51% of the fund's net value, newly entered [4][9]. - Huatai-PineBridge National Biomedicine ETF: 717,879 shares, representing 5.67% of the fund's net value, with an increase of 235,200 shares [4][9].

3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.96亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 从基金十大重仓股角度 责任编辑：小浪快报 3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.96亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层， ...

生物科技ETF基金（516930）四季度增持4400股，持有股数3.26万股，占基金净值比例为3.28%，位居 第九大重仓股。根据测算，今日浮盈赚取约8.28万元。连续3天上涨期间浮盈赚取10.56万元。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.95亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务 ...

3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.96亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 数据显示，嘉实基金旗下4只基金重仓泰格医药股票，合计持有泰格医药187.23万股，按前一日收盘 50.78元，今日截止发稿股价53.32元计算，日浮盈475.57万元。连续3天上涨期间浮盈赚取606.63万元。 | 基金名称 | 基金代 | 基金经理 | 持股数 | 占流通股比 | 占基金净值 | 持股数量变 | | - ...

Core Viewpoint - Tiger Med has seen a significant increase in its stock price, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Nuoan Fund have significant holdings in Tiger Med, totaling 1,001,500 shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of approximately 2.54 million CNY, with a total floating profit of 3.24 million CNY over the past three days [2][8]. - The Nuoan Selected Return Mixed A fund holds 734,922 shares, representing 0.0995% of the circulating shares and 5.63% of the fund's net value, with no change in the number of shares held [3][7]. - The Nuoan Progressive Return Mixed fund holds 266,600 shares, representing 0.0361% of the circulating shares and 5.14% of the fund's net value, also with no change in the number of shares held [3][7].

3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.95亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 从基金十大重仓股角度 数据显示，华商基金旗下4只基金重仓泰格医药股票，合计持有泰格医药82.88万股，按前一日收盘50.78 元，今日截止发稿股价53.32元计算，日浮盈210.52万元。连续3天上涨期间浮盈赚取268.53万元。 | 基金名称 | 基金代 | 基金 | 持股数量 | 占流通股比 | 占基金净值 | 持股 ...

数据显示，德邦基金旗下1只基金重仓泰格医药。德邦大健康灵活配置混合A（001179）四季度增持2.64 万股，持有股数10.64万股，占基金净值比例为4.27%，位居第二大重仓股。根据测算，今日浮盈赚取约 27.03万元。连续3天上涨期间浮盈赚取34.47万元。 德邦大健康灵活配置混合A（001179）成立日期2015年4月29日，最新规模1.41亿。今年以来亏损 4.12%，同类排名6984/8898；近一年亏损2.07%，同类排名7698/8181；成立以来收益45.39%。 3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.95亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、 ...